Surrogate end points for clinical trials of kidney disease progression

被引：115

作者：

Stevens, Lesley A.

Greene, Tom

Levey, Andrew S.

机构：

[1] Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA

[2] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA

来源：

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 1卷 / 04期

关键词：

D O I：

10.2215/CJN.00600206

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：874 / 884

页数：11

共 53 条

[51] Diabetic nephropathy: The proteinuria hypothesis [J].

Williams, ME .

AMERICAN JOURNAL OF NEPHROLOGY, 2005, 25 (02) :77-94

[52] Management of glomerular proteinuria: a commentary [J].

Wilmer, WA ;

Rovin, BH ;

Hebert, CJ ;

Rao, SV ;

Kumor, K ;

Hebert, LA .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (12) :3217-3232

[53] Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease - Results from the AASK trial [J].

Wright, JT ;

Bakris, G ;

Greene, T ;

Agodoa, LY ;

Appel, LJ ;

Charleston, J ;

Cheek, D ;

Douglas-Baltimore, JG ;

Gassman, J ;

Glassock, R ;

Hebert, L ;

Jamerson, K ;

Lewis, J ;

Phillips, RA ;

Toto, RD ;

Middleton, JP ;

Rostand, SG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (19) :2421-2431

← 1 2 3 4 5 6 →